DDIT3 and myxoid liposarcoma: Given that these fusion partners are all FET family members, seclidemstat, as previously mentioned in myxoid liposarcoma harboring EWSR1/FUS–DDIT3 chromosomal translocations, may have promising effects in extraskeletal myxoid chondrosarcoma, considering that seclidemstat, an LSD1 inhibitor, can block transcription of fusions involving FET family members (NCT03600649).